Tag: Brentuximab Vedotin
Phase III ECHELON-1 Clinical Trial of Brentuximab Vedotin Meets Primary Endpoint...
Data from the Phase III ECHELON-1 clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics | Takeda) as part of a frontline combination chemotherapy regimen...
Long-term Data of Brentuximab Vedotin Redifines Treatment of Frontline Mature T-Cell...
Data highlighted at the 59th annual meeting of the American Society of Hematology (ASH) held in Atlanta, Georgia, December 9-12, 2017 shows final five-year...
Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...
This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...
FDA Approves Label Expansion for Brentuximab Vedotin
The approval of brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of adult patients with primary cutaneous anaplastic Large cell lymphoma or pcALC, which...
Supplemental Biologics License Application for Brentuximab Vedotin in Frontline Advanced Hodgkin...
Based on positive results from the Phase III ECHELON-1 Clinical Trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with chemotherapy for the frontline...
Long-Term Data Continues to Support Development Strategy to Establish Brentuximab Vedotin...
Final data from the pivotal phase II trial with brentuximab vedotin (Adcetris®; Seattle Genetics/Takada) in relapsed* or refractory** (r/r) systemic anaplastic large cell lymphoma (sALCL)...
Positive Phase III ECHELON-1 Trial Data Leads to FDA Breakthrough Therapy...
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with chemotherapy for the frontline...
U.S. FDA Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell...
The United States Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the Phase...
Brentuximab Vedotin Approved by Health Canada for Post-ASCT Consolidation Treatment of...
Health Canada, the federal department responsible for helping Canadians maintain and improve their health, has issued a non-conditional marketing authorization for use of brentuximab...
Antibody-drug Conjugates: Technologies and Global Markets
Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new. Due to many technological advances, recognition of appropriate target antigens, success...
